[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535564":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":50,"collaborators":28,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":28,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":28,"enrollmentInfo":62,"targetDuration":28,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":41,"whyStopped":28,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Cosmetique Active International","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"mild to moderate melasma","EXPERIMENTAL","adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)",[13],"Other: tested product",{"label":15,"type":10,"description":16,"interventionNames":17},"mild to moderate acne induced PIHP","adult patients suffering from mild to moderate acne-induced PIHP (IGA) 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"solar lentigo","adult patients suffering from solar lentigo with a pigmentation score \\> 5",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"OTHER","tested product","application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months",[15,9,19],null,[30],{"name":31,"affiliation":32,"role":33},"Steven Thng","National Skin Care Centre","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":28,"email":38},"CONTACT","+65 81253990","steventhng@nsc.com.sg",[40],{"facility":32,"status":41,"city":42,"state":28,"zip":28,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":28},"RECRUITING","Singapore","SG",{"type":45,"coordinates":46},"Point",[47,48],103.85007,1.28967,{"lat":48,"lon":47},{"type":51,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100535564","efficacy-and-tolerability-of-tested-formula-after-3-months-of-treatment-of-facial-hyperpigmentation-of-3-origins-100535564",false,"NCT06253468","Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins","Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo","Inclusion Criteria:\n\n* all phototypes\n* only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo\n* female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study\n* patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study\n\nExclusion Criteria:\n\n* female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study\n* male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)\n* patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.\n* severe melasma, dermal melasma\n* patient with facial pigmentary disorders other than those described in inclusion criteria\n* patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0\u002FBaseline visit\n* patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0\u002FBaseline visit;\n* patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0\u002FBaseline visit",true,"ALL","18 Years",{"count":63,"type":64},72,"ESTIMATED","INTERVENTIONAL",[67],"NA","The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.",[70],"Hyperpigmentation",[72,73,74,19],"facial hyperpigmentation","melasma","acne induced PIHP","2024-08-03",{"date":77,"type":78},"2024-08-06","ACTUAL",{"date":80,"type":78},"2024-06-14",{"date":82,"type":64},"2025-03",{"name":5,"class":6},1]